Time course of the antiproteinuric and antihypertensive effect of @entity9886 in XXXX .

@entity1 @entity6 @entity2316 @entity9886 @entity633 @entity1011 @entity916 @entity551
BACKGROUND: Blockade of the @entity916 -angiotensin system is the primary target in the treatment of @entity2316 . Angiotensin II subtype 1 (AT1) receptor antagonists reduce @entity633 and lower blood pressure, but the initial time course of these effects after initiation of treatment is unknown. We evaluated the time course of the antihypertensive and antialbuminuric effect after initiation of AT1 receptor blockade by @entity9886 in @entity2316 . METHODS: Ten hypertensive type 1 @entity6 @entity1 with @entity2316 were included in the study. After a washout period of 4 weeks, @entity1 received @entity9886 100 mg once daily for 28 days. Every morning, one urine sample was collected for daily determination of albumin/ @entity1011 ratio. Twenty-four hour blood pressure (Takeda TM2420), plasma @entity916 and plasma @entity1011 were measured at baseline and days 7, 14 and 28. RESULTS: Baseline levels of urinary albumin/ @entity1011 ratio and 24 h mean arterial blood pressure were 676 (402-1136) mg/g (geometric mean and 95% CI, respectively) and 100+/-3 mmHg (mean +/- SEM). Albumin/ @entity1011 ratio was significantly reduced after 7 days of treatment by 29% (15-41) (95% CI) without significant further reductions during the 28 day study period (P<0.01 vs baseline). Mean arterial blood pressure was significantly lowered by 7 mmHg after 7 days of treatment and remained unchanged throughout the study (P<0.01 vs baseline). Plasma @entity916 was significantly increased from baseline after initiation of @entity9886 treatment and stabilized after 7 days (P<0.01). We found no changes in plasma @entity1011 during the study. CONCLUSIONS: The initial time course of the @entity551 and @entity633 are concordant, which suggests that systemic and renal haemodynamic mechanisms are of primary importance in the reduction of @entity633 .
